Development and Preclinical Validation of DiaBuddy, a Point-of-Care Decision Support Tool for Children With Type 1 Diabetes: A Pilot Clinical Study (DiaBuddy)

Type 1 Diabetes Mellitus (T1DM) in children requires precise insulin dose adjustments and reliable sick-day decision-making on a daily basis. In real-world practice, families frequently make errors in both domains, predisposing children to hypoglycemia, suboptimal glycemic control, and diabetic ketoacidosis (DKA). Access to structured diabetes education and specialist support is limited in India, creating an unmet need for accessible point-of-care decision support.

DiaBuddy™ is a comprehensive mobile decision-support application for pediatric T1DM developed at Regency Center for Diabetes, Endocrinology and Research, Kanpur. It integrates seven modules aligned with ISPAD 2022 clinical practice guidelines: Insulin Wizard (basal titration, bolus dosing, and correction doses), Sick-Day Guide (stepwise intercurrent illness management), Sugar Tracker (glucose logging with alerts), EatRite (meal planning with carbohydrate quantification using an India-specific food database of 10,245 foods), PlayRite (physical activity guidance), SleepRite (sleep hygiene monitoring), and Knowledge Base (patient and family education).

This study evaluated DiaBuddy™ in two sequential phases. Phase 1 was a preclinical vignette-based validation in which 37 families of children with T1DM independently completed 40 standardized clinical scenarios - 20 insulin-dosing and 20 sick-day - with responses compared against a blinded independent pediatric endocrinologist gold standard. Phase 2 was a prospective single-arm pilot clinical study in which 25 children aged 5 to 18 years with T1DM received structured DiaBuddy™ training and unrestricted home access for three months, with hemoglobin A1c, continuous glucose monitoring metrics, and health-related quality of life assessed at baseline and at three months.

The study aimed to establish whether DiaBuddy™ produces guideline-aligned insulin dosing and sick-day recommendations, whether it outperforms unaided family decision-making, and whether its use over three months is associated with improvements in glycemic control and quality of life in children with T1DM

Study Overview

• Status: Completed
• Conditions: Type 1 Diabetes (T1D)
• Intervention / Treatment: Device: Access to DiaBuddy tool

Detailed Description

Background Optimal management of Type 1 Diabetes Mellitus in children requires frequent insulin dose adjustments based on pre-meal glucose concentrations, carbohydrate content of meals, and personalized parameters including insulin-to-carbohydrate ratio and insulin sensitivity factor. Intercurrent illness requires structured sick-day management to prevent diabetic ketoacidosis. Consistent implementation of these tasks by families in real-world settings is poor, contributing to suboptimal glycemic control and preventable acute complications. Bolus calculators and digital carbohydrate-counting programs have been shown to reduce postprandial glycemic excursions and hypoglycemia in Western populations but no validated tool addressing both insulin dosing and sick-day management existed for Indian children prior to DiaBuddy™.

DiaBuddy™ Application DiaBuddy™ is a comprehensive point-of-care decision support application for pediatric T1DM with seven integrated modules. At enrollment, the clinical team enters the child's honeymoon status, insulin regimen, insulin type, doses, and timing. The Insulin Wizard computes the insulin-to-carbohydrate ratio (500/TDD) and insulin sensitivity factor (1800/TDD for rapid-acting insulin; 1500/TDD for regular insulin). Bolus doses integrate pre-meal glucose, meal carbohydrate content from CarbCal - a proprietary India-specific nutrition database of 10,245 foods - and a default meal target of 120 mg/dL. Basal dose titration follows fasting glucose-linked multipliers. The Sick-Day Guide requests clinical features, capillary blood glucose, and blood or urine ketone values and generates ISPAD-aligned recommendations on hospital admission, total daily dose modification, supplemental rapid-acting insulin dose, and oral fluid type and volume.

Phase 1 - Preclinical Vignette-Based Validation Thirty-seven families of children with T1DM attending the Regency Center for Diabetes, Endocrinology and Research outpatient clinic completed 20 standardized insulin-dosing vignettes (12 bolus, 8 basal) and 20 sick-day management vignettes independently and using DiaBuddy™, blinded to each other's outputs. Vignettes were drafted by two pediatric endocrinologists and reviewed for ISPAD 2022 guideline concordance. A pediatric endocrinologist from a different institution with no financial interest in DiaBuddy™ served as the blinded independent gold standard. Insulin dosing accuracy was quantified using absolute relative deviation (ARD). Sick-day accuracy was evaluated across four domains: hospitalization decision, total daily dose modification, supplemental rapid-acting insulin dose, and fluid type recommendation. Domain-specific weights were pre-specified (hospitalization: 4; supplemental rapid-acting insulin: 3; total daily dose modification: 2; fluid type: 1). Weighted net benefit and prevention index were calculated.

Phase 2 - Pilot Clinical Study A prospective single-arm study enrolled 25 children and adolescents with T1DM (diabetes duration greater than 1 year, age 5 to 18 years) from the same outpatient clinic. The Phase 2 cohort was independent of Phase 1; no participant was enrolled in both phases. At baseline, participants underwent HbA1c measurement, 15 days of intermittently scanned continuous glucose monitoring with FreeStyle Libre 2, and quality of life assessment using the PedsQL questionnaire. Families received structured training on DiaBuddy™ use by a trained research nurse and were provided unrestricted access to the application for home use. After three months, HbA1c, CGM metrics, and quality of life scores were reassessed. Application satisfaction was evaluated using a bespoke 10-item Likert-type rating scale (maximum 50 points). Families were asked whether they wished to continue using the application after study completion. Two participants with incomplete follow-up data and three who withdrew voluntarily were excluded, leaving 20 participants for analysis.

Statistical Analysis Continuous variables were summarized as mean ± standard deviation. Insulin dosing accuracy was quantified using ARD and Bland-Altman analysis. Baseline and post-intervention outcomes were compared using paired t-tests or Wilcoxon signed-rank tests as appropriate. Effect sizes were calculated using Cohen's dz for paired samples. A clinically meaningful improvement in glycemic control was predefined as HbA1c reduction of at least 0.5%. All analyses were performed in SPSS version 23.

Ethics The study was approved by the Institutional Ethics Committee of Regency Hospital Limited, Kanpur (Approval Nos. 16084, 160152, 160151) and conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from parents or guardians and, where applicable, assent from participants prior to enrollment.

Funding This study received no external funding. All resources were provided by Regency Hospital Limited, Kanpur as institutional support. No commercial funding, application licensing fee, or industry contribution was received.

Conflict of Interest Dr. Anurag Bajpai is a co-developer of DiaBuddy™ and holds equity in MedEClinics Private Limited, the company in which DiaBuddy™ is registered. To mitigate potential bias, Dr. Bajpai was not involved in vignette construction, family data collection, or the selection and engagement of the independent expert gold standard. The independent gold standard investigator was affiliated with a different institution and had no financial interest in DiaBuddy™.

• Study Type: Interventional
• Enrollment (Actual): 25
• Phase: Not Applicable

Contacts and Locations

Study Locations

• India
  • Uttar Pradesh
    • Kanpur, Uttar Pradesh, India, 208001
      • Regency Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Diagnosed Type 1 Diabetes Mellitus for more than 1 year Age 5 to 18 years Attending pediatric endocrinology outpatient clinic at Regency Center for Diabetes Endocrinology and Research, Kanpur Caregiver willing and able to use a smartphone application Written informed consent from parent or guardian and assent from participant where applicable

Exclusion Criteria:

• Type 2 diabetes or other forms of diabetes Significant comorbidity is known to independently affect glycemic control No smartphone access in the household Prior use of the DiaBuddy application Incomplete follow-up data at 3 months

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: DiaBuddy™ mobile decision-support application.; Participants recieved DiaBuddy™ mobile decision-support application.	Device: Access to DiaBuddy tool; Children recieved access to DiaBuddy for insulin guidance and sick day management

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Hemoglobin A1c	Change in Hemoglobin A1c	Over three months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
CGM metric	Time in range, time above range, CV	3 months
Quality of life score	PedsQL score	Three months

Collaborators and Investigators

• Sponsor: Regency Hospital Kanpur

Publications and helpful links

General Publications

• Mahapatra A, Paimode S, Banerjee S, Shukla P, Sachan N, Yadav V, Bajpai A. Development and Preclinical Validation of DiaBuddy, a Point-of-Care Decision Support Tool for Children with Type 1 Diabetes: A Pilot Clinical Study. Horm Res Paediatr. Under review. Preprint: medRxiv 2026; MEDRXIV/2026/347874.

Study record dates

Study Major Dates

• Study Start (Actual): July 1, 2025
• Primary Completion (Actual): December 30, 2025
• Study Completion (Actual): December 30, 2025

Study Registration Dates

• First Submitted: March 10, 2026
• First Submitted That Met QC Criteria: March 10, 2026
• First Posted (Actual): March 13, 2026

Study Record Updates

• Last Update Posted (Actual): March 13, 2026
• Last Update Submitted That Met QC Criteria: March 10, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Keywords: Type 1 Diabetes; Insulin dose; Clinical decision support; DiaBuddy; Sick day
• Additional Relevant MeSH Terms: Endocrine System Diseases; Metabolic Diseases; Autoimmune Diseases; Immune System Diseases; Glucose Metabolism Disorders; Diabetes Mellitus; Nutritional and Metabolic Diseases; Diabetes Mellitus, Type 1
• Other Study ID Numbers: Regency-IEC-16084; IEC 16084 / 160152 / 16015 (Other Identifier: Regency Hospital Ethics Committee)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: DescriptionIndividual participant data will not be shared publicly, given the pilot nature of the study and small sample size

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No